Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-01-24
2006-01-24
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S548000, C548S151000, C514S366000
Reexamination Certificate
active
06989379
ABSTRACT:
This invention is directed to triazine derivatives, bicyclic compounds and tricyclic compounds which are selective antagonists for a NPY (Y5) receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. This invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.
REFERENCES:
patent: 3128272 (1964-04-01), Wear et al.
patent: 4383113 (1983-05-01), Levitt et al.
patent: 5166214 (1992-11-01), Billheimer
patent: 5232921 (1993-08-01), Biziere et al.
patent: 5238936 (1993-08-01), Regnier et al.
patent: 5536722 (1996-07-01), Coe et al.
patent: 5550138 (1996-08-01), Sohda
patent: 6124331 (2000-09-01), Marzabadi et al.
patent: 6214853 (2001-04-01), Marzabadi et al.
patent: 6218408 (2001-04-01), Marzabadi et al.
patent: 6222040 (2001-04-01), Marzabadi et al.
patent: 6225330 (2001-05-01), Marzabadi et al.
patent: 6340683 (2002-01-01), Marzabadi et al.
patent: 19824175 (1999-12-01), None
patent: 0448078 (1991-09-01), None
patent: 0283390 (1993-03-01), None
patent: 0432040 (1994-07-01), None
patent: 57151653 (1992-09-01), None
patent: 9323381 (1993-11-01), None
patent: 9418212 (1994-08-01), None
patent: 0775487 (1997-05-01), None
patent: 9619457 (1997-06-01), None
patent: WO9719682 (1997-06-01), None
patent: 9720823 (1997-06-01), None
patent: WO9720823 (1997-06-01), None
patent: 9835944 (1998-08-01), None
patent: 9835957 (1998-08-01), None
patent: 9901128 (1999-01-01), None
patent: 9905138 (1999-02-01), None
patent: WO9932466 (1999-07-01), None
patent: 9932466 (1999-07-01), None
patent: 9962829 (1999-12-01), None
patent: WO9962892 (1999-12-01), None
patent: 0064880 (2000-11-01), None
patent: WO0068197 (2000-11-01), None
patent: 0123389 (2001-04-01), None
patent: WO0123389 (2001-04-01), None
patent: 0144201 (2001-06-01), None
patent: 0164675 (2001-09-01), None
Betancur et al., TIPS vol. 18, 372-386, 1997.
Wieland et al., Expert Opin. Investig. Drugs 9(6): 1327-1346,2000.
McNally, J., et al., “N-(Sulfonamido)alkyl[tetrahydo-1 H-benzo[e]indol-2-yl]amines: Potent Antagonists of Human Neuropeptide Y Y5 Receptor,”Bioorganic&Medicinal Chemistry Letters2000, vol. 10, pp. 213-216.
Wettstein, et al., Central Nervous System Pharmacology of Neuropeptide Y, (1995)Pharmac Ther.65:397-414 (Exhibit B).
U.S. Appl. No. 10/037,859, filed Jan. 3, 2002, Marzabadi et al., Selective NPY (Y5) Antagonists (Triazines) (Exhibit K).
U.S. Appl. No. 10/019,881, filed Dec. 27, 2001, Marzabadi et al., Selective NPY (Y5) Antagonists (Exhibit L).
McNally JJ et al., N-(Sulfonamido)alkyl[tetrohydro-1 H-benzo[e]indol-2-yl]amines: potent antagonists of human neuropeptide Y Y5 receptor, Bioorganic & Medicinal Chemistry Letters 10: 212-216 (2000) (Exhibit Q).
Berlin, K. Darrell and Melvin D. Herd, “Novel 2-Amino-4-Aryl-Substituted- and 2-Amino-4,5-Disubstituted-Thiazoles”,Proc. Okla. Acad. Sci.71: 29-33 (1991).
Brown, D.J., et al., “Unfused Heterobicycles as Amplifiers of Phleomycin. III Thiazolypyridines and Bipyrimidines with Strongly Basic Side Chains”,Aust. J. Chem.34:2423-2429 (1981).
Khazi, et al., “Synthesis and Biological Activity of Some 2-Amino/Arylamino-4H-(1) Benzothiopyrano [4,3-σ] Thiazoles,”J. Hetereocyclic Chem., 4:243-248 (1995).
Ohkubo, M., et al., “Studies on Cerbral Protective Agents. VIII. Synthesis of 2-Aminothiazoles and 2-Thiazolecarboxamides with Anti-anoxic Activity”,Chem. Pharm. Bull., 43(9): 1479-1504 (1995).
Peesapati, V. and N. Lingaiah, “Thiopheno[3,2][1]Benzazepine, Benzo [3,4]Cyclohepta[2,1-b]Thiophenes, Thiazolo[5,4-d][1]Benzazepine and Benzo[3,4]Cyclohepta[2,1-d]Thiazoles”,OPPI Briefs, 25(5):602-606 (1993).
Xia, et al., “Substituted 1,3,5-Triazines as Cholesteryl Ester Transfer Protein Inhibitors,”Bioorg. Med. Chem. Lett.6(7):919-922 (1966).
Yamane, Kameji,Nippon Kagaku Zasshi, 91(4):395-399 (1970).
Yamane, et al.,Nippon Kagaku Zasshi, 90(6):569-571 (1969); and.
Yamane, et al.,Nippon Kagaku Zasshi,89(6):612-614 (1968).
Desai Manesh N.
Marzabadi Mohammad R.
Noble Stewart A.
Wong Wai C.
Balasubramanian Venkataraman
H. Lundbick A/S
Kalinchak Stephen G.
LandOfFree
Selective NPY (Y5) antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective NPY (Y5) antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective NPY (Y5) antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3600220